Lincoln Pharmaceuticals is currently trading at Rs 28.75, up by 1.35 points or 4.93% from its previous closing of Rs 27.40 on the BSE.
The scrip opened at Rs 30.00 and has touched a high and low of Rs 30.00 and Rs 27.50 respectively. So far 1160 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 54.00 on 14-Sep-2010 and a 52 week low of Rs 26.10 on 17-Aug-2011.
Last one week high and low of the scrip stood at Rs 31.95 and Rs 26.10 respectively. The current market cap of the company is Rs 45.59 crore.
The promoters holding in the company stood at 24.54% while Non-Institutions held 75.46% stake in the company.
Lincoln Pharmaceuticals (LPL) recently announced the launch of its ayurvedic product named as ‘ISL Granuels’ that will serve the mother and child healthcare segment. ISL Granules takes care of solving the breast feeding problems by initiating breast milk secretion and sustaining the secretion as mother’s milk is crucial for the survival of the newborn. The product without causing any side effects also has ingredients to improve the general health of the mother.
ISL Granules developed by LPL contains the extracts of eight proven herbs and natural calcium that is available in a delicious chocolate-flavoured drink formulation and for this the company has worked extensively on ayurvedic herbs. The product is developed by Teresa, a speciality division of LPL that exclusively serves the mother and child health care segment. Currently the company exports to more than 45 countries and has its own manufacturing facilities in Ahmedabad.
Lincoln Pharmaceuticals was established to manufacture and market affordable therapeutic products. The company has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters. There are three different buildings for tablets, capsules and injectables and also a separate building for quality control.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
